Recommendations for diagnosis and treatment of vasospastic disorders (Raynaud‘s phenomenon)

  • Janez Poklukar Splošna bolnišnica Jesenice
  • Martina Plešivčnik Novljan Klinični oddelek za revmatologijo Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Mija Mulej Splošna bolnišnica Jesenice
  • Alojzija Hočevar Klinični oddelek za revmatologijo Univerzitetni klinični center Ljubljana Zaloška 7 1000 Ljubljana
  • Metka Prešeren Štrukelj Univerzitetni rehabilitacijski inštitut Republike Slovenije Linhartova cesta 51 1000 Ljubljana
  • Matija Kozak Klinični oddelek za žilne bolezniUniverzitetni klinični center LjubljanaZaloška 7 1000 Ljubljana
DOI: https://doi.org/10.6016/ZdravVestn.2663
Keywords: spasm of the arteries, pallor of the digits when cold, cyanosis

Abstract

In the article diagnostic and therapeutic recommendations for the treatment of patients with suspected vasospastic disorders (Raynaud‘s phenomenon) are presented. All recommendations are evaluated according to evidence and general agreement.

Downloads

Download data is not yet available.

References

Herrick AL. Pathogenesis of Raynaud‘s phenomenon.Rheumatology (Oxford). 2005 May;44(5):587-96.

Huges M, Herric AL. Raynaud‘sphenomenon. BestPractice&Res ClinRheum 2016;30:112-32.

Belch J.Raynaud‘s phenomenon.Mini-review.CardiovascRes 1997;33:25-30.

Maricq HR,Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I. Geographic variation in the prevalence of Raynaud‘s phenomen: a 5 region comparision. J Rheumatol 1997;24:879-89.

Freedman RR, Mayes MD. Familial aggregation of primary Raynaud‘s disease. ArthritisRheum 1996;39:1189-91.

Brown KM, Middaugh SJ, Haythornthwaite JA, Bielory L. Te effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud‘s attacks. J Behav Med 2001;24:137-53.

Wigley FM. Raynaud‘s phenomenon. N Engl J Med 2002;347:1001-8.

Maverakis E, Forum Patel F, Kronenberg D, Chung L, Fiorentino D,Allanore Y, et al, InternationalConsensusCriteriafortheDiagnosisofRaynaud’sPhenomenon. J Autoimmun 2014;0:60-5.

Spencer-Green G. Outcomes in primary Raynaud‘s phenomenon. Arch Intern Med 1998;158:595-600

LeRoy EC, Medsger TA Jr. Raynaud‘s phenomenon: a proposal for classifcation. Clin Exp Rheumatol 1992;10:485.

Cleophas TJM, Niemeyer MG. Raynaud‘s syndrome, an enigma afer 130 years. Angiology 1993;196-209.

Landry GJ, Edwards JM, McLafferty RB, et al. Long–term outcome of Raynaud‘s syndrome in a prospectively analyzed patient cohort. J Vasc Surg 1996;23:76.

Vayssairat M, Baudot N, Blaison N, Evenouu P, Gilard M, Mathieu JF. Limitations of cold tests in Raynaud‘s diseases. J Ml Vasc 1990;15:82-5.

Maricq HR, Jennings JR, Valter I, Frederick M, Tompson B, Smith EA, Hill R; Raynaud‘s treatment Study Investigators. Evaluation of treatment efcacy of Raynaud phenomenon by digital pressure response to cooling. Vasc Med 2000;5:135-40.

Drug therapy for peripheral vascular disease. A national clinical guideline. Dosegljivo na :http:// www. guideline.gov

Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud‘s phenomenon. BMJ.2012 Feb 7;344:e289. doi: 10.1136/bmj.e289.

Middaugh SJ, Haythornthwaite JA, Tompson B, Hill R, Brown KM, Freedman RR, Attanasio V, Jacob RG, Scheier M, Smith EA. Te Raynaud‘s Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Appl Psychophysiol Biofeedback 2001;26:251-78.

Tompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud‘s phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.

Tompson AE, Pope JE. Calcium channel blockers for primary Raynaud‘s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005 Feb;44(2):145-50

Ennis H1, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud‘s phenomenon. Cochrane Database Syst Rev. 2014 Jan 30;1:CD002069. doi: 10.1002/14651858.CD002069.pub4.

Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin Raynaud‘s syndrome. Ann Rheum Dis 1985;44:754-60.

Belch JJF, Newman P, Drury JK, Capell H, Lieberman P, Forbes CD, Prentice CR. Intermittent epoprostenol ( prostacyclin) infusion in patients with Raynaud‘s syndrome: a double-blind controlled trial. Lancet 1983;1:313-5.

Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayers M, et al. Intravenous iloprost treatment of Raynaud‘s phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.

Scorza R. Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E. Effects of long-termcyclic iloprost therapy in systemic sclerosis of Raynaud‘s phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfeld NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.Oral iloprost treatment in patients with Raynaud‘s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.Arthritis Rheum. 1998 Apr;41(4):670-7.

Pope J1, Fenlon D, Tompson A, Shea B, Furst D, Wells G, Silman A. Iloprost and cisaprost for Raynaud‘s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953.

Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud‘s phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.J Rheumatol. 1996 Nov;23(11):1917-20.

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L. ELUAR recomendations for the treatment of systemic sclerosis: a report from EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.

Hummers LK1, Dugowson CE, Dechow FJ, Wise RA, Gregory J, Michalek J, Yenokyan G, McGready J, Wigley FM.A multicentre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis. 2013 Dec;72(12):1962-7. doi: 10.1136/annrheumdis-2012-201536. Epub 2012 Dec 25.

Herrick AL. Modifed-release sildenafl reduces Raynaud’s phenomenon attack frequencyin limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.

Schiopu E, Vivien M, Impens A, Rothman J, McCloskey D, Wilson J, et al. Randomizedplacebo-controlled crossover trial of tadalafl in Raynaud’s phenomenon secondary tosystemic sclerosis. J Rheumatol 2009;36:2264-8.

Shenoy P, Kumar S, Lalan KJ, Choudhary C, Singh U, Misra R, et al. Efcacy of tadalaflin secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheematology (Oxford) 2010;49:2420-8.

Dziadzio M, Denton CP, Smith R, Howell A, Blann A, Bowers E, et al. Losartan therapyfor Raynaud’s phenomenon and scleroderma. Arthritis Rheum 1999;42:2646-55.

Wigley F M. Clinical manifestation and diagnosis of Raynaud‘s phenomenon. 2012 UpToDate, www.uptodate.com.

Engelhart M. Te effect of sympathetic blockade and cooling in Raynaud’s phenomenon. Clin Physiol 1990;10:131.

Taylor MH, McFadden JA, Bolster MB, Silver RM. Ulnar artery involvement in systemic sclerosis (scleroderma).J Rheumatol 2002;29(1):102-6.

Published
2018-01-30
How to Cite
1.
Poklukar J, Plešivčnik Novljan M, Mulej M, Hočevar A, Prešeren Štrukelj M, Kozak M. Recommendations for diagnosis and treatment of vasospastic disorders (Raynaud‘s phenomenon). TEST ZdravVestn [Internet]. 30Jan.2018 [cited 25Apr.2024];86(11-12):553-61. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2663
Issue
Vol 86 No 11-12 (2017): November - December
Section
Professional Article

Copyright (c) 2018 Slovenian Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.